216 related articles for article (PubMed ID: 38115619)
1. Tebentafusp as a Promising Drug for the Treatment of Uveal Melanoma.
Al Balushi K; Al Hadhrami A; Balushi HA; Al Lawati A; Das S
Curr Drug Targets; 2024; 25(3):149-157. PubMed ID: 38115619
[TBL] [Abstract][Full Text] [Related]
2. Tebentafusp in advanced uveal melanoma: proof of principle for the efficacy of T-cell receptor therapeutics and bispecifics in solid tumors.
Liu AW; Wei AZ; Maniar AB; Carvajal RD
Expert Opin Biol Ther; 2022 Aug; 22(8):997-1004. PubMed ID: 35060440
[TBL] [Abstract][Full Text] [Related]
3. Overall Survival Benefit with Tebentafusp in Metastatic Uveal Melanoma.
Nathan P; Hassel JC; Rutkowski P; Baurain JF; Butler MO; Schlaak M; Sullivan RJ; Ochsenreither S; Dummer R; Kirkwood JM; Joshua AM; Sacco JJ; Shoushtari AN; Orloff M; Piulats JM; Milhem M; Salama AKS; Curti B; Demidov L; Gastaud L; Mauch C; Yushak M; Carvajal RD; Hamid O; Abdullah SE; Holland C; Goodall H; Piperno-Neumann S;
N Engl J Med; 2021 Sep; 385(13):1196-1206. PubMed ID: 34551229
[TBL] [Abstract][Full Text] [Related]
4. Tebentafusp for the treatment of HLA-A*02:01-positive adult patients with unresectable or metastatic uveal melanoma.
Chen LN; Carvajal RD
Expert Rev Anticancer Ther; 2022 Oct; 22(10):1017-1027. PubMed ID: 36102132
[TBL] [Abstract][Full Text] [Related]
5. Tebentafusp for the treatment of metastatic uveal melanoma.
Schank TE; Hassel JC
Future Oncol; 2022 Apr; 18(11):1303-1311. PubMed ID: 35172589
[TBL] [Abstract][Full Text] [Related]
6. Tebentafusp: a novel drug for the treatment of metastatic uveal melanoma.
Wang Z; Xie Y; Wang JQ; Cheng Y; Fleishman J; Chen ZS; Chen Y
Drugs Today (Barc); 2023 Mar; 59(3):179-193. PubMed ID: 36847626
[TBL] [Abstract][Full Text] [Related]
7. Tumor lysis syndrome induced by tebentafusp.
Ruf T; Leonhardt A; Anz D; Kunz WG; Röhrle N; Foerster P; Tomsitz D; French LE; Seegräber M; Heinzerling L
Immunotherapy; 2023 Nov; 15(16):1363-1368. PubMed ID: 37661909
[TBL] [Abstract][Full Text] [Related]
8. Three-Year Overall Survival with Tebentafusp in Metastatic Uveal Melanoma.
Hassel JC; Piperno-Neumann S; Rutkowski P; Baurain JF; Schlaak M; Butler MO; Sullivan RJ; Dummer R; Kirkwood JM; Orloff M; Sacco JJ; Ochsenreither S; Joshua AM; Gastaud L; Curti B; Piulats JM; Salama AKS; Shoushtari AN; Demidov L; Milhem M; Chmielowski B; Kim KB; Carvajal RD; Hamid O; Collins L; Ranade K; Holland C; Pfeiffer C; Nathan P
N Engl J Med; 2023 Dec; 389(24):2256-2266. PubMed ID: 37870955
[TBL] [Abstract][Full Text] [Related]
9. Tebentafusp: First Approval.
Dhillon S
Drugs; 2022 Apr; 82(6):703-710. PubMed ID: 35364798
[TBL] [Abstract][Full Text] [Related]
10. New immunotherapy approaches as the most effective treatment for uveal melanoma.
Eteghadi A; Ebrahimi M; Keshel SH
Crit Rev Oncol Hematol; 2024 Feb; 194():104260. PubMed ID: 38199429
[TBL] [Abstract][Full Text] [Related]
11. Uveal melanoma: In the era of new treatments.
Wespiser M; Neidhardt E; Negrier S
Cancer Treat Rev; 2023 Sep; 119():102599. PubMed ID: 37473516
[TBL] [Abstract][Full Text] [Related]
12. Tebentafusp in the Treatment of Metastatic Uveal Melanoma: Patient Selection and Special Considerations.
Montazeri K; Pattanayak V; Sullivan RJ
Drug Des Devel Ther; 2023; 17():333-339. PubMed ID: 36785760
[TBL] [Abstract][Full Text] [Related]
13. Successful treatment of metastatic uveal melanoma with ipilimumab and nivolumab after severe progression under tebentafusp: a case report.
Reiter S; Schroeder C; Broche J; Sinnberg T; Bonzheim I; Süsskind D; Flatz L; Forschner A
Front Oncol; 2023; 13():1167791. PubMed ID: 37207136
[TBL] [Abstract][Full Text] [Related]
14. The antihelminthic drug niclosamide effectively inhibits the malignant phenotypes of uveal melanoma
Zhou J; Jin B; Jin Y; Liu Y; Pan J
Theranostics; 2017; 7(6):1447-1462. PubMed ID: 28529629
[TBL] [Abstract][Full Text] [Related]
15. Tebentafusp in the treatment of metastatic uveal melanoma - the first patient treated in the Czech Republic.
Klabusay M; Bábková B
Klin Onkol; 2024; 38(2):134-138. PubMed ID: 38697822
[TBL] [Abstract][Full Text] [Related]
16. Novel Approaches to the Systemic Management of Uveal Melanoma.
Khan S; Carvajal RD
Curr Oncol Rep; 2020 Jul; 22(10):104. PubMed ID: 32725406
[TBL] [Abstract][Full Text] [Related]
17. Tebentafusp, A TCR/Anti-CD3 Bispecific Fusion Protein Targeting gp100, Potently Activated Antitumor Immune Responses in Patients with Metastatic Melanoma.
Middleton MR; McAlpine C; Woodcock VK; Corrie P; Infante JR; Steven NM; Evans TRJ; Anthoney A; Shoushtari AN; Hamid O; Gupta A; Vardeu A; Leach E; Naidoo R; Stanhope S; Lewis S; Hurst J; O'Kelly I; Sznol M
Clin Cancer Res; 2020 Nov; 26(22):5869-5878. PubMed ID: 32816891
[TBL] [Abstract][Full Text] [Related]
18. Overall survival from tebentafusp versus nivolumab plus ipilimumab in first-line metastatic uveal melanoma: a propensity score-weighted analysis.
Piulats JM; Watkins C; Costa-García M; Del Carpio L; Piperno-Neumann S; Rutkowski P; Hassel JC; Espinosa E; de la Cruz-Merino L; Ochsenreither S; Shoushtari AN; Orloff M; Salama AKS; Goodall HM; Baurain JF; Nathan P
Ann Oncol; 2024 Mar; 35(3):317-326. PubMed ID: 38048850
[TBL] [Abstract][Full Text] [Related]
19. In vitro and in vivo anti-uveal melanoma activity of JSL-1, a novel HDAC inhibitor.
Wang Y; Liu M; Jin Y; Jiang S; Pan J
Cancer Lett; 2017 Aug; 400():47-60. PubMed ID: 28455241
[TBL] [Abstract][Full Text] [Related]
20. Uveal melanoma: A pathologist's perspective and review of translational developments.
Schoenfield L
Adv Anat Pathol; 2014 Mar; 21(2):138-43. PubMed ID: 24508696
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
